1. Stevens, F.J., Analysis of protein-protein interaction by simulation of small-zone size-exclusion chromatography: Application to an antibody-antigen association, Biochemistry

2. Sung, M., Poon, G.M.K., and Gariepy, J., The importance of valency in enhancing the import and cell routing potential of protein transduction domain-containing molecules, Biochim. Biophys. Acta 1758, 355-363, 2006.

3. Schellman, J.A. and Schellman, C., The conformation of polypeptide chains in proteins, in The Proteins, 2nd edn., Vol. 2, ed. H. Neurath, Academic Press, New York, pp. 1-137, Chapter 7, 1964.

4. Fasman, G.D., Prediction of Protein Structure and the Principles of Protein Conformation, Plenum Press, New York, 1989.

5. Nall, B.T. and Dill, K.A., Conformation and Forces in Protein Folding, AAAS, Washington, DC, 1991.

6. Merz, K.M. and Le Grand, S.M., The Protein Folding Problem and Tertiary Structure Prediction, Birkhäuser, Boston, MA, 1994.

7. Schellekens, H., Biosimilar therapeutic agents: Issues with bioequivalence and immuno-genicity, Eur. J. Clin. Invest. 341, 797-799, 2004.

8. Kessler, M., Goldsmith, D., and Schellekens, H., Immunogenicity of biopharmaceuti-cals, Nephrol. Dial. Transplant. 21(Suppl. 5), v9-v12, 2006.

9. Gerrazani, A.A., Biggio, G., Caputi, A.P. et al., Biosimilar drugs: Concerns and opportunities, BioDrugs 21, 351-356, 2007.

10. Roger, S.D. and Mikhail, A., Biosimilars: Opportunity or cause for concern? J. Pharm. Pharm. Sci. 10, 405-410, 2007.

11. Pavlovic, M., Girardiin, E., Kapetaneovic, L. et al., Similar biological medicinal products containing recombinant human growth hormone: European regulation, Horm. Res. 69, 14-21, 2008.

12. Moran, N., Fractured European market undermines biosimilar launches, Nat. Biotechnol.

13. Kawanishi, T., Regulatory perspective from Japan—Comparability of biopharmaceuti-cals, Biologicals 34, 65-68, 2006.

14. Lubiniecki, A.S. and Federici, M.M., Comparability is not just analytical equivalence, Biologicals 34, 45-47, 2006.

15. Kuhlmann, M. and Covic, A., The protein science of biosimilars, Nephrol. Dial. Transplant. 21(Suppl 5), v4-v8, 2006.

16. Deechongkit, S., Aoki, K.H., Park, S.S., and Kerwin, B.A., Biophysical comparability of the same protein from different manufacturers: A case study using Epoetin alfa from Epogen and Eprex, J. Pharm. Sci. 95, 1931-1943, 2006.

17. Heavner, G.A., Arakawa, T., Philo, J.S. et al., Protein isolated from biopharmaceutical formulations cannot be used for comparative studies: Follow-up to a "case study" using Epoetin Alpha Form Epogen and EPREX, J. Pharm. Sci. 96, 3214-3225, 2007.

18. ICH 5QE: Comparability of biotechnological/biological products subject to changes in their manufacturing process, International Committee on Harmonisation, http://www.;, 2005.

19. DeFelippis, M.R. and Larimore, F.S., The role of formulation in insulin comparability studies, Biologicals 34, 49-54, 2006.

20. Petriccciani, J., A global view of comparability concepts, Dev. Biol. (Basel) 106, 9-13, 2002.

21. Moos, M. Jr., Regulatory philosophy for comparability protocols, Dev. Biol. (Basel) 109, 53-56, 2002.

22. Chirino, A.J. and Mire-Sluis, A., Characterizing biological products and assessing comparability following manufacturing changes, Nat. Biotechnol. 22, 1383-1391, 2004.

23. Simek, S.L., Characterization of gene therapy products and the impact of manufacturing changes on product comparability, Dev. Biol. (Basel) 122, 139-144, 2005.

24. Robertson, J.S., Changes in biological source material, Biologicals 34, 61-63, 2006.

25. Sewerin, K., Shacter, E., Robertson, J., and Wallerius, C., Changes in biological source materials, Biologicals 34, 71-72, 2006.

26. Johnson, W.C. Jr., Protein secondary structure and circular dichroism: A practical guide, Proteins 7, 205-214, 1990.

27. Yada, R.Y., Jackman, R.L., and Nakai, S., Secondary structure prediction and determination of proteins—A review, Int. J. Pept. Protein Res. 31, 98-108, 1988.

28. Andersen, C.A. and Rost, B., Secondary structure assignment, Methods Biochem. Anal. 44, 341-363, 2003.

29. Pelton, J.T. and McLean, L.R., Spectroscopic methods for analysis of protein secondary structure, Anal. Biochem. 277, 167-176, 2000.

30. Xie, M. and Schowen, R.L., Secondary structure and protein deamidation, J. Pharm. Sci. 88, 8-13, 1999.

31. Blow, D.M., Chymotrypsin: Tertiary structure and enzymic activity, Biochem. J. 110, 2P, 1968.

32. Crippen, G.M., Correlation of sequence and tertiary structure in globular proteins, Biopolymers 16, 2189-2201, 1977.

33. Richardson, J.S., Describing patterns of protein tertiary structure, Methods Enzymol. 115, 341-358, 1985.

34. Barton, G.J. and Sternberg, M.J., A strategy for the rapid multiple alignment of protein sequence. Confidence levels from tertiary structure comparisons, J. Mol. Biol. 198, 327-337, 1987.

35. Wang, C.X., Shi, Y.Y., and Huang, F.H., Fractal study of tertiary structure of proteins, Phys. Rev. A 41, 7043-7048, 1998.

36. Meiler, J. and Baker, D., Coupled prediction of protein secondary and tertiary structure, Proc. Natl. Acad. Sci. USA 100, 12105-12110, 2003.

37. Shen, B.W., Spiegel, P.C., Chang, C.H. et al., The tertiary structure and domain organization of coagulation factor VIII, Blood 111, 1240-1247, 2008.

38. Sela, M., Anfinsen, C.B., and Harrington, W.F., The correlation of ribonuclease activity with specific aspects of tertiary structure, Biochim. Biophys. Acta 26, 502-512, 1957.

39. Anfinsen, C.B., The tertiary structure of ribonuclease, Brookhaven Symp. Biol. 15, 184-198, 1962.

40. Anfinesen, C.B., The formation of the tertiary structure of proteins, Harvey Lect. 61, 95-116, 1967.

41. Mire-Sluis, A.R., Challenges with current technology for the detection, measurement and characterization of antibodies against biological therapeutics, Dev. Biol. (Basel) 109, 59-69, 2002.

42. Hermeling, S., Crommelin, D.J.A., Schellekens, H., and Jiskout, W., Structure-immuonogenicity relationships of therapeutic proteins, Pharm. Res. 21, 897-803, 2004.

43. Sampaio, C., Costa, J., and Ferreira, J.J., Clinical comparability of marketed formulations of botulinum toxin, Mov. Disord. 19(Suppl 8), S129-S136, 2004.

44. Frost, H., Antibody-mediated side effects of recombinant proteins, Toxicology 209, 155-160, 2005.

45. Thorpe, R. and Swanson, S.J., Current methods for detecting antibodies against erythropoietin and other recombinant proteins, Clin. Diag. Lab. Immunol. 12, 28-39, 2005.

46. Romer, T., Peter, F., Saenger, P. et al., Efficacy and safety of a new ready-to-use recombinant human growth hormone solution, J. Endocrinol. Invest. 30, 578-589, 2007.

47. Henderson, C.J., Holme, M.J., and Aitken, R.J., Analysis of the biological properties of antibodies raised against native and deglycosylated porcine zonae pellucidae, Gamete Res. 16, 323-341, 1987.

48. Aouffen, M., Paquin, J., De Grandpre, E. et al., Deglycosylated ceruloplasmin maintains its enzymatic, antioxidant, cardioprotective, and neuronoprotective properties, Biochem. Cell Biol., 79, 489-497, 2001.

49. Raju, T.S., Briggs, J.B., Chamow, S.M. et al., Glycoengineering of therapeutic glycoproteins: In vitro galactoxylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues, Biochemistry 31, 8868-8876, 2001.

50. Jefferis, R., Glycosylation of recombinant antibody therapeutics, Biotechnol. Prog. 21, 11-16, 2005.

51. Walsh, G. and Jefferis, R., Post-translational modifications in the context of therapeutic proteins, Nat. Biotechnol. 24, 1241-1252, 2006.

52. Jefferis, R., Antibody therapeutics: Isotype and glycoform selection, Expert Opin. Biol. Ther. 7, 1401-1413, 2007.

53. Temporini, C., Calleri, E., Massolini, G., and Caaccialanza, G., Integrated analytical strategies for the study of phosphorylation and glycosylation in proteins, Mass Spectrom. Rev. 27, 207-236, 2008.

54. Crommelin, D.J.A., Storm, G., Verrijk, R. et al., Shifting paradigms: Pharmaceutical versus low molecular weight drugs, Int. J. Pharmaceut. 266, 3-16, 2003.

55. Kato, Y., High-performance hydrophobic interaction chromatography of proteins, Adv. Chromatogr. 26, 97-115, 1987.

56. Arakawa, T. and Narhi, L.O., Solvent modulation in hydrophobic interaction chromatography, Biotechnol. Appl. Biochem. 13, 151-172, 1991.

57. Wu, S.-L. and Karger, B.L., Hydrophobic interaction chromatography of proteins, Methods Enzymol. 270, 27-47, 1996.

58. Hemstrom, P. and Irgum. K., Hydrophilic interaction chromatography, J. Sep. Sci. 29, 1784-1821, 2006.

59. Lienqueo, M.E., Mahn, A., Salgado, J.C., and Asenjo, J.A., Current insights on protein behavior in hydrophobic interaction chromatography, J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 849, 53-68, 2007.

60. Tarvers, R.C., Calcium-dependent changes in properties of human prothrombin: A study using high-performance size-exclusion chromatography and gel-permeation chromatog-raphy, Arch. Biochem. Biophys. 241, 639-648, 1985.

61. Wu, S.L., Figueroa, A., and Karger, B.L., Protein conformational effects in hydrophobic interaction chromatography. Retention characterization and the role of mobile phase additives and stationary phage hydrophobicity, J. Chromatogr. 371, 3-27, 1986.

62. Withka, J., Moncuse, P., Baziotis, A., and Maskiewicz, R., Use of high-performance size-exclusion, ion-exchange, and hydrophobic interaction chromatography for the measurement of protein conformational change and stability, J. Chromatogr. 398, 175-202,

0 0

Post a comment